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Abnormal accumulations of amyloid-b (Ab)-peptides are one of the pathological hallmarks of Alzheimer’s
disease (AD). The precursor of the Ab-peptides, the amyloid precursor protein (APP), is also found in
peripheral blood cells, but its function in these cells remains elusive. We previously observed that mono-
nuclear phagocytes release Ab-peptides during activation and phagocytosis, suggesting a physiologic role
in inﬂammatory processes.
Here, we show that supplementing the media with soluble N-terminally truncated Ab(2–40) and Ab(2–42)
as well as Ab(1–42) induced the phagocytosis of polystyrene particles (PSPs) by primary human monocytes.
If the PSPs were pre-incubated with Ab-peptides, phagocytosis was induced by all tested Ab-peptide
species. N-terminally truncated Ab(x–42) induced the phagocytosis of PSPs signiﬁcantly more effectively
than did Ab(x–40). Similarly, the phagocytosis of Escherichia coli by GM-CSF- and M-CSF-elicited macro-
phages as well as microglia was particularly facilitated by pre-incubation with N-terminally truncated
Ab(x–42). The proinﬂammatory polarization of monocytes was indicated by the reduced MSRI expression
and IL-10 secretion after phagocytosis of PSPs coated with Ab(1–42), Ab(2–42) and Ab(3p–42). Polarization of
the macrophages by GM-CSF reduced the phagocytic activity, but it did not affect the capabilities of
Ab-peptides to opsonize prey.
Taken together, Ab-peptides support phagocytosis as soluble factors and act as opsonins. Differential
effects among the Ab-peptide variants point to distinct mechanisms of interaction among monocytes/
macrophages, prey and Ab-peptides. A proinﬂammatory polarization induced by the phagocytosis of
Ab-peptide coated particles may provide a model for the chronic inﬂammatory reaction and sustained
plaque deposition in AD.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Background
Amyloid-b (Ab)-peptides, the primary components of neuritic
plaques found in brains of Alzheimer’s disease (AD), are generated
by the proteolytic processing of the b-amyloid precursor protein
(APP) (Selkoe, 2011; De Strooper et al., 2012). Beneath the b- and
c-secretases, several other proteases, such as meprin-b, caspase
and aminopeptidase A, seem to be involved in this process
(Takeda et al., 2004; Sevalle et al., 2009; Bien et al., 2012). Thereby
more than 40 different N- and C-terminally truncated and modiﬁed
variants of the Ab-peptides are generated (Maler et al., 2007).
APP is also present in the immune cells of the central nervous
system (CNS) and the periphery, particularly microglia and
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Spitzer et al., 2010). The induction of APP and Ab-peptide secretion
in activated mononuclear phagocytes suggests a role for APP in the
initiation of immune responses (Monning et al., 1990; Sondag and
Combs, 2004).
Both, the expression of surface receptors and cytokine secretion
by macrophages and microglia are context sensitive. Thus, proin-
ﬂammatory M1- and anti-inﬂammatory M2-polarized mononu-
clear phagocytes represent the extremes of a heterogeneous
continuum (Mantovani et al., 2004; Varnum and Ikezu, 2012).
Although helpful as a model for investigating the basic functions
of mononuclear phagocytes, recent research has identiﬁed several
intermediate stages and cells that express M1 and M2 markers
simultaneously (Xue et al., 2014).
In brain sections from AD patients, microglia predominately
presented markers of M1 polarization (Michelucci et al., 2009;
Varnum and Ikezu, 2012; Sudduth et al., 2013). The proinﬂamma-
tory polarization of microglia was shown to inhibit the clearance of
Ab-peptides and might therefore favor the accumulation of
Ab-peptides and consequent neuronal cell death, ﬁnally leading
to cognitive deterioration and behavioral disturbances
(Yamamoto, 2008).
Several studies have investigated the phagocytosis of Ab-pep-
tides as a means to eliminate them from the organism, but data
on a potential physiological role for Ab-peptides in the process of
phagocytosis are scarce. Reduced levels of Ab-peptides in CSF are
found not only in AD but also in several other neuroinﬂammatory
diseases, such as borreliosis, herpes encephalitis and bacterial
meningitis, with normalization after successful treatment
(Sjogren et al., 2001; Krut et al., 2013). Similarly, the CSF levels
of the soluble APP fragments sAPPa and sAPPb are reduced in mul-
tiple sclerosis and Lyme neuroborreliosis (Mattsson et al., 2009,
2010). Furthermore, systemic bacterial infections are considered
to be a risk factor for sporadic AD, connecting infection, inﬂamma-
tion and alterations in amyloid metabolism and leading to cogni-
tive disturbances (Dunn et al., 2005; Honjo et al., 2009;
Eikelenboom et al., 2012).
A potential function of the Ab-peptides in this context may be to
opsonize pathogens to support their clearance and/or act as soluble
factors with cytokine or chemokine activities. We have previously
reported that monocyte activation by the phagocytosis of polysty-
rene beads induces APP glycosylation and Ab-peptide secretion
(Spitzer et al., 2010). We observed a relative increase in the release
of N-terminally truncated Ab peptide species from activated mono-
cytes (Maler et al., 2008; Spitzer et al., 2010). In the current study,
we used mononuclear phagocytes as a model to investigate the
impact of various Ab-peptides on the phagocytosis of polystyrene
particles or Escherichia coli bacteria and on concurrent macrophage
polarization.2. Methods
2.1. Cell isolation and culture
Human peripheral blood mononuclear cells (PBMCs) were iso-
lated by Ficoll (Biochrom, Germany) density gradient centrifuga-
tion from buffy coats purchased at Transfusionsmedizin Suhl,
Germany. Thrombocytes were removed by under-laying an FCS-
gradient and centrifugation at 75g for 15 min. Monocytes were
isolated from PBMCs by the antibody-mediated removal of non-
monocytes using a MACSMonocyte Isolation Kit II (Miltenyi Biotec,
Germany) and MACS LS Columns (Miltenyi Biotec, Germany). For
the analysis of undifferentiated monocytes, the cells were resus-
pended in serum-free AIM-V medium and seeded at a density of
1  106 cells/ml in 96-well ultra-low attachment plates (Corning,USA). Differentiated macrophages were obtained by cultivating
monocytes for seven days at 8  105 cells/ml in RPMI 1640 with
10% FCS in 96-well plates (Biochrom, Germany). For the polariza-
tion of macrophages, 40 ng/ml rhGM-CSF (Immunotools, Germany)
or 80 ng/ml rhM-CSF (Immunotools, Germany) was added to the
culture medium, respectively. After three days, 50% of the medium
was exchanged.
THP-1 cells were obtained from ATCC and maintained below
1  106 cells/ml in RPMI 1640 supplemented with 10% FCS. For dif-
ferentiation to macrophages, THP-1 cells were cultured at 2  106
cells/ml for three days in RPMI 1640 medium supplemented with
10% FCS and 50 ng/ml phorbol 12-myristate 13-acetate (PMA,
Sigma–Aldrich, Germany).
Primary cultures of porcine microglia were isolated following a
protocol adapted from Franke (Franke et al., 2000). Brieﬂy, the
secretory areas, cerebellum and meninges were removed from
brain hemispheres obtained from a local abattoir. After mincing
the tissue, it was incubated for 2 h with 6.5% (v/v) dispase (BD,
Germany) at 37 C. Lipids were removed by mixing 100 mL of the
cell suspension with 150 mL of dextran solution (q = 1.0621 g/
mL), followed by centrifugation at 6800g for 10 min at 4 C. The
tissue was further homogenized by ﬁltration (180 lm), trituration
and consecutive incubation for 30 min with 1 mg/mL collagenase/
dispase (Roche, Germany). The cell suspension was layered onto a
two-level percoll gradient with q = 1.08 and q = 1.04 g/mL. Mixed
brain cells were collected from the lower interface of the gradient
and were washed and seeded in Dulbecco’s modiﬁed eagle’s med-
ium, supplemented with 10% fetal calf serum and antibiotics.
Microglia were collected after 7 days by gently washing the conﬂu-
ent cell layer and collecting the loosely adherent cells. Finally, the
microglia were plated in RPMI medium supplemented with 10%
fetal calf serum and antibiotics at a density of 0.8  106/mL in
96-well plates.
2.2. Staining of inducible nitric oxide synthase (iNOS) in macrophages
After seven days in vitro, macrophages were detached with
Accutase (PAA, Germany) supplemented with 2 mmol EDTA for
45 min at 37 C and ﬁxed with 2% paraformaldehyde on poly-l-
lysine-coated slides for 60 min at room temperature. Subse-
quently, the cells were permeabilized and blocked in PBS with 1%
bovine serum albumin (BSA)/5% goat serum/0.2% Triton-X-100
for 1 h at room temperature. Labeling with mouse anti-human
iNOS monoclonal antibody (R&D Systems, USA) was performed at
a concentration of 20 lg/ml for 80 min at room temperature fol-
lowed by staining with secondary antibody AF488 goat anti-mouse
(Invitrogen, Germany) for 1 h at room temperature. Slides were
mounted with Roti-Mount FluorCare DAPI (Roth, Germany), and
images were acquired on a Nikon eclipse 80i microscope equipped
with NIS-elements BR 3.1 software.
2.3. Coating of polystyrene particles and E. coli bacteria with
Ab-peptides
Ab(1–40), Ab(1–42), Ab(2–40), Ab(2–42), Ab(3p–42) and Ab(5–42) (all
Anaspec, USA) were reconstituted in 1% NH4OH, diluted with
H2Odd to reach a ﬁnal concentration of 1 mg/ml in H2Odd/0.08% NH4-
OH and stored in aliquots at 20 C. Yellowgreen Flouresbrite
(Polysciences, Germany) polystyrene particles (PSP) with a diameter
of 1 lmwere resuspended at 4.55  1010 particles/ml in the respec-
tive Ab-peptide solution for 12 h at 37 C. After washing, the parti-
cles were centrifuged at 10,000g for 10 min and suspended in PBS.
For the phagocytosis assay, the particles were diluted in the
appropriate cell culture medium to reach a ﬁnal concentration of
1.5 108 particles/ml. The coating of PSP with bovine serum
albumin (BSA, Sigma, Germany) was performed equivalently.
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were reconstituted at 20 mg/ml in H2Odd with 2 mM sodium azide
and coated with the respective Ab-peptides, BSA or opsonizing
reagent (OpsR, Invitrogen, Germany) as described above. The
E. coli were diluted in cell culture medium to reach a ﬁnal
concentration of 0.8  108 particles/ml.pHrodo Green-labeled
E. coli BioParticles (Invitrogen, Germany) were reconstituted at
2 mg/mL in PBS and were treated equivalently.
The amount of Ab-peptide bound to the polysterene particles
was assessed by staining with Ab-peptide-speciﬁc antibodies and
measurement by ﬂow cytometry. Therefore, 4.55  106 particles
in 100 ll PBS were incubated with 1 lg of the Ab-peptide-speciﬁc
mouse anti-human monoclonal antibody 6E10 or 4G8 (Covance,
USA) for 30 min at 4 C. The particles were washed in PBS and
incubated with an AF-488-labeled secondary antibody (Invitrogen,
Germany) for 30 min at 4 C. After washing with PBS, the particles
were suspended in Jonosteril (Fresenius Kabi, Germany) for ﬂow
cytometric analysis.2.4. Quantiﬁcation by ﬂow cytometry of in vitro phagocytosis
Immediately before the experiments, the medium was
exchanged and the cells were pre-incubated for 2 h with the Ab-
peptides (1 lg/ml) or 5 lM cytochalasin D where indicated. Then,
PSPs or AF488 E. coli were added at a ﬁnal concentration of
4.65  106 particles/ml or 5  106 particles/ml, respectively.
pHrodo Green-labeled E. coli were added at a concentration of
50 lg/mL. Opsonizing reagent was used as a positive control when
the phagocytosis of AF488 E. coli was assessed.
For the phagocytosis of PSPs and E. coli particles, monocytes,
THP macrophages, monocyte-derived macrophages and porcine
microglia were incubated at 37 C for 20 h, 4 h, 2 h and 4 h, respec-
tively. THP macrophages were detached with 2.5% trypsin for
30 min. Accutase supplemented with 2 mmol EDTA was used
for the detachment of monocyte-derived macrophages and
microglia. Phagocytosis was evaluated by the mean ﬂuorescence
intensity (MFI) of phagocytes as a measure of the number of cell-
associated ﬂuorescent PSPs. The non-speciﬁc binding of the beads
to the cell membrane was assessed by pretreating the culture for
2 h with 5 lM cytochalasin D.2.5. Differentiation of monocytes with Ab-peptide-coated PSP
The isolation of human monocytes was performed as described
above. The cells were cultured in 24-well plates (Biochrom,
Germany) for three days at a density of 1.2  106 cells/ml in RPMI
1640 medium supplemented with 10% FCS. The coating of
non-ﬂuorescent PSP with a diameter of 1 lm (Micromod, Germany)
with Ab-peptides and BSA was performed as described above. PSPs
were added to the cell cultures at a ﬁnal concentration of
1.24  107 particles/ml for 72 h.2.6. Expression of surface antigens on macrophages
A total of 1  105 detached cells were incubated with ﬂuores-
cence-labeled monoclonal mouse anti-human MSRI-pe (R&D Sys-
tems, USA), IL1-RI-pe, IL1-RII-ﬁtc (BD Pharmingen, Germany),
HLA-DR-ﬁtc, CD11b-ﬁtc, CD14-pe (Immunotools, Germany) and
CD 206-ﬁtc (R&D Systems, USA) or with an appropriate isotype
control for 30 min at 4 C. Following incubation, samples were
diluted with Jonosteril (Fresenius Kabi, Germany) and measured
on a CyFlow space (Partec, Germany) using the FlowMax 2.81
software.2.7. Measurement of IL-10 and TNFa production
After 72 h of monocyte cultivation with PSP, the supernatants
were harvested and stored at 20 C until further analysis. The
IL-10 and TNFa levels were measured using the DuoSet ELISA
kit (R&D Systems, USA) according to the manufacturer’s
instructions.2.8. Statistical analysis
Statistical analysis was performed using the GraphPad Prism
6.0 software. All independent experiments were repeated at least
four times. The data are expressed as the mean ± SD. Signiﬁcant
differences were evaluated using ANOVA followed by the
Neuman–Keuls post test. To detect the differences in macrophage
differentiation, ANOVA for paired samples was used, followed by
Fisher’s least signiﬁcant different test. Correlations were evaluated
by Spearman’s test. The criterion of signiﬁcance was set to p < 0.05.3. Results
3.1. Soluble Ab-peptides enhanced the phagocytosis of PSPs by human
monocytes
To investigate the effect of soluble Ab-peptides on the phagocy-
tosis of PSPs by freshly isolated human monocytes, the cells were
pre-incubated with 1 lg/ml of the respective Ab-peptide in cell
culture medium. Then, 20 h after adding the ﬂuorescent PSPs,
phagocytosis was quantiﬁed by ﬂow cytometry. The MFI of the
phagocytes was used as a measure of the number of internalized
ﬂuorescent particles. The pre-incubation of monocytes with
Ab(1–42) as well as the N-terminally truncated Ab(2–40) and
Ab(2–42), but not Ab(1–40), induced phagocytosis at levels signiﬁ-
cantly above the control levels (p < 0.05) (Fig. 1A). Monocytes trea-
ted with Ab(2–40) internalized 17% more PSPs than those treated
with full-length Ab(1–40) (p < 0.05). The treatment of cells with
BSA did not inﬂuence the phagocytosis of PSPs.3.2. Pre-incubation with N-truncated Ab(2–42) increased the
phagocytosis of PSPs by human monocytes most efﬁciently
To assess whether the Ab-peptides secreted by monocytes
enhanced phagocytosis by binding to pathogens, the effect of Ab-
coated PSPs on their phagocytosis by humanmonocytes was exam-
ined. The phagocytosis of ﬂuorescent particles was quantiﬁed by
ﬂow cytometry as described above (Fig. 1B). Precoating the ﬂuores-
cent PSPs with all of the tested Ab-peptides increased their phago-
cytosis by monocytes compared to the phagocytosis of uncoated
PSP (p < 0.001). Coating the PSPs with Ab(1–42) enhanced the
amount of phagocytosed PSPs by 40% (p < 0.0001). Ab(1–42) induced
phagocytosis more effectively than Ab(1–40) (p < 0.0001). The treat-
ment of monocytes with Ab(2–42) and Ab(3p–42)-coated PSPs
resulted in an even higher increase of the MFI values by 53%
(p < 0.0001) and 56% (p < 0.0001), respectively. This result indi-
cates that an additional N-truncation of Ab(1–42) further increased
the phagocytosis of PSPs. In contrast to the treatment of monocytes
with soluble Ab-peptides, pre-incubation with n-truncated Ab(2–40)
did not enhance phagocytosis more effectively than Ab(1–40).
Because undifferentiated monocytes are poor phagocytes, cytocha-
lasin D only weakly reduced phagocytosis. Phagocytosis of pHrodo
Green-labeled E. coli, which is only ﬂuorescent at an acidic pH,
revealed that cytochalasin D completely inhibited phagocytosis
in our setting (Fig. 4F). Therefore, increased signal intensity after
pretreatment with cytochalasin D and coincubation with
Fig. 1. Ab-peptides facilitate phagocytosis by opsonizing prey. Ab-peptide variants were added to the cell culture medium of freshly isolated monocytes (A) or differentiated
THP-1 macrophages (C) at a concentration of 1 lg/mL. Alternatively, PSPs were pre-incubated with Ab-peptide variants and added to cultures of monocytes (B) or THP-1
macrophages (D). The mean ﬂuorescence intensity (MFI) of the phagocytes as a measure of the number of internalized ﬂuorescent PSPs was quantiﬁed by ﬂow cytometric
analysis (black bars). Unspeciﬁc binding of the particles to the phagocytes was evaluated by adding 5 lM cytochalasin D to the medium (gray bars). The values of MFI are
expressed relative to the untreated control cells (% of Con). The data represent the mean ± SD of ﬁve independent experiments. BSA = bovine serum albumin.
CytD = cytochalasin D ⁄p < 0.05; ⁄⁄p < 0.01; ⁄⁄⁄p < 0.001.
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phagocyte surface without internalization.3.3. Differential effects of Ab-peptides on phagocytosis of PSP were not
caused by different binding afﬁnities of the peptides for PSPs
To investigate whether the differential effects of the Ab-pep-
tides were due to different binding afﬁnities for the PSPs, the
amount of Ab-peptide bound to the PSPs was quantiﬁed by immu-
nostaining with the C- and N-terminal non-speciﬁc Ab antibodies
6E10 and 4G8. Ab-peptide-speciﬁc immunoﬂuorescence detected
on the PSPs did not differ between the Ab-peptide species at coat-
ing concentrations of 1.0 mg/ml and 0.5 mg/ml (Fig. 2A and B).
Because coating was performed at a concentration of 1.0 mg/ml,
the observed effects on phagocytosis were not caused by the
binding of different amounts of Ab-peptides to the PSPs. Of note,
compared to the other Ab-peptide variants, more Ab(2–40) bound
to the PSP at the lower coating concentrations of 0.1 mg/ml and
0.05 mg/ml.3.4. Phagocytosis of PSPs coated with Ab(x–42) induced a
proinﬂammatory state in monocytes
During the phagocytosis of Ab-peptide-coated PSPs, the expres-
sion of several pro- and anti-inﬂammatory markers were examined
by ﬂow cytometry and ELISA. Coating of the PSPs with Ab(1–42),
Ab (2–40), Ab (2–42) and Ab (3p–42) caused a 25–35% decrease in
MSRI expression on the phagocytes compared to uncoated PSPs
(p < 0.05). No signiﬁcant effect was observed for Ab(1–40) – or
BSA-coated PSPs (Fig. 3A). Additionally, no signiﬁcant alteration
of the IL1 receptors or of CD206 was observed after coating the
particles with Ab peptides (Fig. 3B–D).The IL-10 and TNFa levels were measured in cell culture super-
natants after 72 h of phagocytosis of the Ab-coated PSPs (Fig. 3E
and F). The measurements were well above the limit of detection
(1.56 pg/ml), and the coefﬁcient of variation was below 25%.
Compared to the phagocytosis of uncoated PSPs, the IL-10 levels
were decreased by 20–30% only in monocytes treated with
Ab(x–42)coated PSPs (p < 0.01). Neither Ab(x–40) nor BSA-coated
PSPs changed the IL-10 expression in monocytes. The TNFa levels
were only increased by coating the particles with Ab2–40.
The reduced expression of MSRI and the lower secretion of IL-10
indicate an induction of a proinﬂammatory polarization of mono-
cytes during phagocytosis of Ab(x–42) coated PSP.
3.5. In THP-1 macrophages, phagocytosis was induced by PSPs coated
with Ab-peptides but not by soluble Ab-peptides in the culture medium
To assess the effects of Ab-peptides on the phagocytosis of
in vitro-differentiated phagocytes, THP-1 macrophages were ana-
lyzed in the assay described above. In contrast to human mono-
cytes, the phagocytosis activity of THP-1 macrophages was not
increased after adding soluble Ab-peptides to the cell culture med-
ium (Fig. 1C). Similar to freshly prepared monocytes, coating PSPs
with all tested Ab-peptides resulted in increased phagocytosis
(p < 0.0001) (Fig. 1D). Among the untruncated Ab(1-x) peptides,
Ab(1–42) was more active than Ab(1–40) in stimulating the phagocy-
tosis of PSPs (p < 0.05). Coating PSPs with N-terminally truncated
Ab(2–40) and Ab(2–42) resulted in higher MFI values when compared
to Ab(1–40) and Ab(1–42)-coated PSPs, respectively (p < 0.05). The
strongest induction of phagocytosis was observed with Ab(2–42);
compared to uncoated PSPs, the MFI values increased by 150%
(p < 0.0001). Interestingly, Ab(3p–42) was less effective than
Ab(2–42) in THP-1 macrophages, which is in contrast to our observa-
tions in primary human monocytes.
Fig. 2. Equal amounts of all Ab-peptide variants on PSPs at a coating concentration
of 1.0 mg/ml. PSPs were pre-incubated with Ab-peptide variants at different
concentrations. The amount of peptide bound to the PSP was measured by ﬂow
cytometry after staining with Ab-speciﬁc antibodies 6E10 (A) or 4G8 (B) and is
presented as the MFI of the particle. The data represent the mean ± SD of four
independent experiments.
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coating the bacteria with N-terminally truncated Ab(x–42)
Fluorescent, AF488-labeled E. coli were coated with the respec-
tive Ab-peptides, and their phagocytosis was quantiﬁed by ﬂow
cytometry to investigate whether Ab-peptides also act differen-
tially on the phagocytosis of natural pathogens (Fig. 4G). Whereas
no effect on the phagocytosis of E. coli was observed with the
Ab(1-x) isoforms, the phagocytosis of E. coli was strongly and exclu-
sively enhanced by N-terminally truncated Ab(2–42). A tendency to
induce phagocytosis was also observed for Ab(3p–42). This ﬁnding
conﬁrms that N-terminally truncated Ab(x–42) also induces phagocy-
tosis when bound to E. coli. As previously observed during the
phagocytosis of PSPs, the opsonizing effect of Ab(3p–42) was less pro-
nounced in THP-macrophages than in primary human phagocytes.
3.7. Ab(x–42)-mediated phagocytosis of E. coli by primary human
macrophages and porcine microglia
As differentiation and polarization have a great impact on the
phagocytic activity of macrophages, primary human monocyte-
derived GM-CSF- and M-CSF-elicited macrophages were compared.
The differentiation and polarization of monocytes by GM-CSF and
M-CSF were conﬁrmed by phase contrast microscopy, iNOS immu-
noﬂuorescence, ﬂow cytometry and ELISA (Fig. 4A). GM-CSF-
derived macrophages displayed higher expression of iNOS and
CD206. The expression of MSRI, HLA-DR and CD14 was higher inM-CSF-elicited macrophages (Fig. 4B). Furthermore, the secretion
of TNFa tended to be higher in GM-CSF-derived macrophages,
whereas that of IL-10 was higher in M-CSF-derived macrophages
(Fig. 4C). Therefore, GM-CSF-elicited macrophages shared several,
but not all, of the features of M1 macrophages, whereas M-CSF-
derived macrophages rather resembled M2 macrophages. Again,
Ab-peptides terminating at amino acid position 40 did not increase
the uptake of AF488-labeled E. coli. Pre-incubation with n-trun-
cated Ab(x–42) increased the uptake of E. coli most effectively, inde-
pendent of macrophage polarization. In GM-CSF-derived
macrophages, coating with Ab(1–42), Ab(2–42) and Ab(3p–42) resulted
in 55–70% increases in the uptake of E. coli (p < 0.01). Most inter-
estingly, Abx–42 induced phagocytosis even more effectively than
a commercial opsonizing (OpsR) reagent intended to facilitate
the phagocytosis of E. coli (Fig. 4D). Ab5–42 also induced the phago-
cytosis of pHrhodo Green-labeled E. coli. However, this effect was
weaker than that with Ab1–42 (Fig. 4F). Although a coating concen-
tration of 1 mg/mL was chosen for the comparison of the Ab pep-
tide variants, a dose response analysis with Ab1–42 revealed
500 lg/mL to be the least effective coating concentration when
applied in our paradigm (Supplementary Fig. 1).
In the M-CSF-derived macrophages, similar effects were obvi-
ous (Fig. 4E). N-terminally truncated Ab(3p–42) stimulated the
uptake of E. coli most efﬁciently. The MFI values increased by
67% (p < 0.0001). This effect was only slightly stronger after coating
the E. coli with the opsonizing reagent (OpsR). Ab(1–42) was again
more effective than Ab(1–40), which did not inﬂuence phagocytic
activity (p < 0.0001).
The good correlation of ﬂuorescent signal intensities between
cultures with and without cytochalasin D (r = 0.78 for GM-CSF-
and r = 0.74 for M-CSF-elicited macrophages, both p < 0.001) sug-
gested that the Ab peptides increased the phagocytosis of the prey
by increasing its binding to the phagocytes (Supplementary Fig. 2).
No such correlation was observed when using pHrodo Green-
labeled particles, which were only ﬂuorescent in acidic compart-
ments (r = 0.13; p = 0.41).
Consistent with the published data, the total number of parti-
cles ingested by M-CSF-derived macrophages was twice as high
as those taken up into GM-CSF-derived macrophages, independent
of the coating of the particles (MFI: 47.13 ± 17.05 vs. 24.53 ± 5.37;
p < 0.0001).
Primary porcine microglia were generated by separating loosely
adherent cells from conﬂuent mixed cortical cultures. Labeling by
phagocytosis and CD14 revealed a purity of approximately 80%.
When incubated with the Ab peptide-coated AF488-labeled
E. coli, the ﬁndings with macrophages could be reproduced. Again,
the preincubation of E. coli with Ab1–42 and Ab3p-42 increased its
uptake by phagocytes, with Ab3p–42 being more active than
Ab1–42 (Fig. 5).
The results obtained in human macrophages and microglia con-
ﬁrmed that the coating of particles with N-terminally truncated
Ab(x–42) facilitates phagocytosis more effectively than coating
with the other tested Ab-peptides. Although M-CSF-derived
macrophages showed higher phagocytic activity, the impact of
Ab-peptides was independent of the polarization of the macrophages.
4. Discussion
The present study provides evidence for an immunological
function of Ab-peptides as soluble factors and as opsonins, both
of which promote the phagocytosis of pathogens. The effect of
the Ab-peptides depends on N- and C-terminal modiﬁcations. A
proinﬂammatory phenotype is particularly induced by Ab-peptides
that terminate at alanine 42.
The phagocytosis of PSPs was facilitated by pre-incubation with
all of the tested Ab-peptide variants. Among them, Ab(x–42) was
Fig. 3. Reduced expression of MSRI and reduced secretion of IL-10 after phagocytosis of PSPs coated with Ab(x–42). Freshly isolated monocytes were cultivated with Ab-
peptide-coated PSPs for 72 h. Surface expression of the MSRI, CD206, IL1-RI and IL1-RII was quantiﬁed by ﬂow cytometry (A–D). The IL-10 and TNFa levels in the conditioned
media were determined by ELISA (E, F). The results are expressed in relation to untreated cells (% of Con). The data represent the mean ± SD of four independent experiments.
Asterisks above the data indicate signiﬁcance compared to the control. ⁄p < 0.05; ⁄⁄p < 0.01; ⁄⁄⁄p < 0.001.
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ticles was previously observed in microglia after coating micro-
spheres or yeast particles with Ab(1–42) (Kopec and Carroll, 1998;
Choucair-Jaafar et al., 2011). No such effect was reported after
coating with Ab1–40 (Choucair-Jaafar et al., 2011). These reports
and our data indicate that the C-terminus strongly impacts the
phagocytosis-inducing effect of Ab-peptides.
In primary monocytes and THP-1 macrophages, the phagocyto-
sis of Ab-coated particles was further increased by the N-terminal
truncation of Ab(x–42), i.e., Ab(2–42) and Ab(3p–42). As Ab-peptides are
highly hydrophobic, incubating particles with these peptides
increases their hydrophobicity. Among the Ab-peptides, those end-
ing with alanine 42 are more hydrophobic than Ab(x–40). N-trunca-
tion and pyroglutaminylation at amino acid residue 3 further
enhance hydrophobicity due to the loss of charged groups (Pike
et al., 1995; Schilling et al., 2006; Schlenzig et al., 2009; Meral
and Urbanc, 2013). Hydrophobicity of the Ab-peptides is also
correlated with their aggregation propensity. Hence, the differ-
ences observed between the Ab-peptide variants may also come
from a heterogeneity in the size of Ab-aggregates coated to the
PSPs. However, oligomeric Ab-peptides were reported to inhibitphagocytosis. (Pan et al., 2011). We therefor assume that the
observed effect is not due to Ab-peptide aggregation. In bacteria,
increasing hydrophobicity facilitates their uptake by macrophages
(Absolom, 1988; Tsuda et al., 2000; Nakano et al., 2008). Similarly,
the phagocytosis-inducing effects of the different Ab-peptide vari-
ants observed in our experiments correlated with their calculated
hydrophobicity. Hydrophobicity is one of the hallmark characteris-
tics of damage-associated molecular patterns (DAMP) (Seong and
Matzinger, 2004). Cell damage or bacterial invasion is indicated
whenever a hydrophobic domain of a protein is presented to the
immune system. The receptors recognizing hydrophobic DAMPs
are referred to as pattern recognition receptors (PRR), such as
Toll-like or Scavenger receptors (Seong and Matzinger, 2004). For
binding to PRR, hydrophobicity is the main predictive feature,
and the binding interactions do not depend on the exact molecular
conﬁguration (Seong and Matzinger, 2004). The Ab-peptides
reportedly bind several PRRs, such as TLR2, TLR4 or CD36
(Salminen et al., 2009). Association with pathogens to increase
hydrophobicity and improve the activation of PRR is a mechanism
that has also been described for other proteins, such as surfactant
or ﬁbronectin (Seong and Matzinger, 2004). The concentration
Fig. 4. Ab(x–42) enhances the phagocytosis of E. coli by human macrophages. Characteristics of GM-CSF- and M-CSF-elicited macrophages are shown by the phase-contrast
microscopic expression of inducible nitric oxide synthase (iNOS) (A), surface expression of MSRI, HLA DR, IL1-RI, IL1-RII CD11b, CD14 and CD206 (B) and secretion of TNFa
relative to IL10 (C). Fluorescent AF-488 E. coli were coated with bovine serum albumin (BSA), opsonizing reagent (OpsR) or the respective Ab-peptide variant and added to
GM-CSF (D, F), M-CSF (E) or THP-1 (G) macrophage cultures. The number of internalized E. coli was evaluated by ﬂow cytometry as indicated above (black bars). Unspeciﬁc
binding of the particles to the phagocytes was evaluated by adding 5 lM cytochalasin D to the medium (gray bars). To control for the activity of cytochalasin D and to
differentiate phagocytosis from unspeciﬁc binding, pHrodo Green-labeled E. coliwere added to GM-CSF-elicited macrophages (F). The MFI values are expressed relative to the
phagocytosis of uncoated E. coli (% of CON). The data represent the mean ± SD of four independent experiments. ⁄p < 0.05; ⁄⁄p < 0.01; ⁄⁄⁄p < 0.001.
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approximately 1000-fold higher than that found in CSF or serum
(Lewczuk et al., 2008; Lewczuk, 2009). Microdialysis experiments
in patients with traumatic brain injury suggested Ab1–42 concen-
trations between 10 and 200 pg/mL in interstitial ﬂuid
(Tsitsopoulos and Marklund, 2013). However, the concentrations
at the region of Ab-peptide secretion are unknown and are most
likely magnitudes higher than those measured at a steady state
in the whole compartment. Through microdialysis, it was shown
that stress or electrical activity could essentially increase the regio-
nal concentration of Ab peptides (Cirrito et al., 2005; Kang et al.,
2007). In the case of AD, it has been suggested that the reduced
concentration of Ab1–42 in the CSF of AD patients was due to
impaired transport of Ab-peptides from the interstitial ﬂuid into
the CSF (Spies et al., 2012). The concentration of Ab peptides in
the interstitial ﬂuid and especially in direct proximity to the pla-
ques is therefore most likely increased in AD. Taken together, our
data suggest that Ab-peptides bound to particles facilitate phago-
cytosis. Opsonizing pathogens, in particular with N-terminallytruncated Ab(x–42), may therefore be a means to support phagocy-
tosis in inﬂammatory processes.
In line with our study showing that soluble Ab-peptides also
induce the phagocytosis of ﬂuorescent PSPs by monocytes, an
enhanced uptake of particles was previously reported after prim-
ing microglia with soluble Ab(1–42) (Kopec and Carroll, 1998). In
addition to full-length Ab(1–42), soluble N-terminally truncated
Ab(2–40) and Ab(2–42) increased the uptake of PSP in our experi-
ments. In contrast to phagocytosis of Ab-coated particles, Ab(1–40)
and Ab(3p–42) did not enhance phagocytosis when added to the cul-
tures in a soluble form. This result indicates the involvement of dif-
ferent receptors for soluble Ab-peptides than those that are bound
to particles.
Our data show that the Ab-peptide variants differ in their effect
on mononuclear phagocytes, indicating distinct receptor binding
proﬁles. This activity might explain why the strong phagocytosis-
inducing effect of some Ab-peptide variants (e.g., Ab(1–42), Ab(2–40)
and Ab(2–42)) in monocytes was missing in differentiated macro-
phages that express a different repertoire of surface receptors.
Fig. 5. Ab(x–42) enhances the phagocytosis of E. coli by porcine microglia. Porcine
microglia was challenged with Ab peptide, bovine serum albumin (BSA) or
opsonizing reagent (OpsR)-coated ﬂuorescent AF488-labeled E. coli BioParticles
(black bars). The addition of cytochalasin D (CytD) in one experiment revealed the
unspeciﬁc binding of E. coli to the microglia (gray bars). The MFI values are
expressed relative to the phagocytosis of uncoated E. coli (% of Con). The data
represent means ± SDs of four independent experiments. ⁄p < 0.05; ⁄⁄p < 0.01;
⁄⁄⁄p < 0.001.
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Ab(3p–42) may be due to the different receptor proﬁle of this cell
line. Therefore, it is essential to separately investigate the impact
of each Ab-peptide variant for each cell type. Distinct functions
of Ab-peptides are also reﬂected by the cell-speciﬁc secretion pro-
ﬁles of Ab-peptide variants and by the different Ab-peptide proﬁles
in body ﬂuids (Maler et al., 2007, 2009).
It was assumed that the binding of Ab-peptides to microglia is
deleterious, as this binding initiates a proinﬂammatory reaction
leading to neuronal cell death (Rojo et al., 2008; Eikelenboom
et al., 2011; Fricker et al., 2012; Neniskyte and Brown, 2013). In
contrast, a physiological role for APP and Ab-peptides in the
immune system was suggested, as both induce chemotaxis in
human monocytes and neutrophils (Tiffany et al., 2001; Kaneider
et al., 2004). A relation between the immune system and
Ab-peptide metabolism is further supported by the observation
of reduced Ab-peptide levels in the CSF during the course of
infectious diseases of the CNS, such as meningitis or borreliosis
(Krut et al., 2013).
One source of the N-terminally modiﬁed Ab-peptides detected
in human plasma is the mononuclear phagocyte system (Maler
et al., 2008). These cells are activated by phagocytosis, and they
express higher levels of APP and release Ab-peptides with
increased proportions of N-terminally truncated Ab(x–40) species
(Ledoux, 1993; Spitzer et al., 2010). Remarkably, these N-terminally
truncated Ab(x–40) variants, when added in a soluble form to the cell
culture medium, induced the phagocytosis of PSPs in primary
human monocytes more effectively than other variants. Therefore,
soluble Ab-peptides, and especially N-terminally truncated
variants secreted by mononuclear phagocytes, may act as auto- or
paracrine pro-phagocytic factors employed by undifferentiated
monocytes.
After the phagocytosis of Ab-peptide-coated PSPs, we observed
decreased levels of IL-10 secretion and MSRI expression by macro-
phages, indicating the beginning of a proinﬂammatory M1 polari-
zation (Mantovani et al., 2004). Reduced secretion of IL-10 upon
stimulation with Ab1-40 was previously observed in cultures of
whole blood cells (Speciale et al., 2007). The missing increase in
TNFa secretion and no obvious change in CD206 expression might
indicate that the activation of macrophages by Ab peptides was not
clear-cut M1 polarization but was instead a mixed state with some
preference for M1 characteristics. Although helpful as a basic
model, dichotomous separation of M1 and M2 macrophagesseemed to be an oversimpliﬁcation. There has been increasing evi-
dence that macrophages and microglia primarily express markers
of both extremes and that each stimulus results in a speciﬁc acti-
vation state (Xue et al., 2014). Microglia in a Tg2576 AD mouse
model were shown to express genes of classical activation (TNFa
and NOS2), together with genes associated with an alternative acti-
vation (CD206, ariginase I, chitinase-3-like-3) (Colton et al., 2006).
This heterogeneity was also found in brain samples from AD
patients (Sudduth et al., 2013). Interestingly, receptors binding
Ab-peptides such as TLR4, TLR2, RAGE or Scavenger receptors can
induce pro- as well as antiinﬂammatory reactions of phagocytes
for example by NFjB or MAPK signaling (Salminen et al., 2009;
Canton et al., 2013; Zhang et al., 2014). In line with our data,
Michelucci and colleagues found that the phagocytosis of Ab1–42
oligomeres induced markers that were associated with the M1
polarization of microglia (Michelucci et al., 2009). M1 polarization
markers are especially induced by those Ab-peptide variants that
accumulate in Ab-plaques during the course of AD (Guntert et al.,
2006). Most likely as a consequence, microglia in the brains of
AD patients shows signs of M1 polarization (Michelucci et al.,
2009; Varnum and Ikezu, 2012; Sudduth et al., 2013).
Several studies have shown, in murine AD models, that inhibit-
ing the proinﬂammatory M1 polarization of microglia with omega-
3 fatty acids, IL10 or IL4 improved cognitive performance and
reduced AD neuropathology (Varnum and Ikezu, 2012; Hjorth
et al., 2013). The general proinﬂammatory M1 polarization of
phagocytes is also found outside the CNS in AD patients (Varnum
and Ikezu, 2012). Proinﬂammatory cytokines, which induce M1
polarization, seem to inhibit the clearance of Ab by macrophages
(Town et al., 2005; Yamamoto, 2008). This activity might be
explained by the observed lower phagocytosis rate of M1 com-
pared to M2 macrophages. However, we found that the phagocyto-
sis-inducing effect of Ab-peptides was similar in M1 and M2
macrophages. This result indicates that opsonizing pathogens with
Ab-peptides improves phagocytosis, but a concurrent differentia-
tion in the direction of M1macrophages may ameliorate this effect.
In the pathogenesis of AD, Ab peptides that terminate after AA
42, particularly the N-terminally truncated and pyroglutaminylat-
ed variant Ab3p-42, have been considered important pathogenic
agents (Portelius et al., 2010; Wittnam et al., 2012). They are the
main components of neuritic plaques, and the toxicity of Ab1–42
and, even more signiﬁcantly, Ab3p–42 toward neurons has been well
established (Wirths et al., 2009; Portelius et al., 2010; Becker et al.,
2013). Consequently, the inhibition of glutaminyl cyclase, which
catalyzes the pyroglutaminylation step, is considered a potential
treatment for AD (Alexandru et al., 2011).
Another approach to stopping AD progression that is currently
under clinical investigation is the inhibition of BACE1. Interest-
ingly, inhibitors of BACE1 reduced Ab1-x species, with a relative
increase in the N-terminally truncated Ab peptide variants, such
as Ab5-x (Takeda et al., 2004; Portelius et al., 2011; Mattsson
et al., 2012). In our experiments, we found Ab5–42 to support the
phagocytosis of E. coli. There has been growing evidence that the
secretion of N-terminally truncated Ab-peptides is not dependent
on BACE1. An enzyme suggested to be involved in this process is
meprin-b (Bien et al., 2012). Meprin-b is also expressed by mono-
nuclear phagocytes, and meprin deﬁciency has been associated
with a dysfunction of monocytes, leading to reduced immunere-
sponsiveness (Crisman, 2004; Sun et al., 2009).
Several other lines of evidence support the idea of chronic sys-
temic inﬂammation as the driving force in plaque deposition, link-
ing it with immunosenescence and a consequently lower immune
responsiveness in AD (Malavolta et al., 2013). For example, several
pro-inﬂammatory cytokines, such as TNFa, IL1b and IL6, are
increased in AD, natural killer cells seem to be normal in frequency
but defective in function and there is a general decline in T-cell
124 M. Condic et al. / Brain, Behavior, and Immunity 41 (2014) 116–125responsiveness (Solerte et al., 2000; Swardfager et al., 2010; Jadidi-
Niaragh et al., 2012; Monsonego et al., 2013). Cashman et al. sug-
gested that Ab-aggregation in AD is a result of impaired innate
immunity together with defective Ab phagocytosis (Cashman
et al., 2008). Furthermore, monocytes from patients with AD are
deﬁcient in PRR expression, and mitogen-stimulated whole-blood
cell cultures from AD patients secrete lower levels of proinﬂamma-
tory cytokines (Richartz et al., 2005; Fiala et al., 2007).
We propose that the production and phagocytosis of Ab pep-
tides is, as with reactive oxygen species, a tightly regulated defense
mechanism of the immune system in the blood and brain. Distur-
bances of this homeostasis might lead to amyloid deposition, neu-
rodegeneration and ﬁnally dementia. Currently, one can speculate
whether the defective clearance of Ab-peptides in patients with AD
is the result of reduced immune responsiveness and that this
reduced immune responsiveness may result from a primary energy
toward Ab-peptides.
5. Conclusion
The present study indicates that soluble and surface-bound
Ab-peptides facilitate phagocytosis depending on the length of their
N- and C-termini and that they induce a proinﬂammatory polariza-
tion of the phagocytes. On one hand, these ﬁndings indicate a phys-
iological function of Ab-peptides. On the other hand, an Ab-driven
proinﬂammatory M1 polarization impairing phagocytosis may
provide a model for self-sustained plaque deposition.
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